Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy (Q38805897)

6 September 2017

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy (English)

1 reference

6 September 2017

1 reference

6

L Zitvogel

0 references

Guido Kroemer

5

G Kroemer

0 references

Alexander Eggermont

3

A Eggermont

0 references

Jean-Charles Soria

4

J-C Soria

0 references

Aurélien Marabelle

2

A Marabelle

0 references

author name string

J M Pitt

1

1 reference

6 September 2017

A Marabelle

2

1 reference

6 September 2017

J-C Soria

4

1 reference

6 September 2017

language of work or name

1 reference

10 April 2016

1 reference

6 September 2017

1 reference

6 September 2017

27

1 reference

6 September 2017

8

1 reference

6 September 2017

1482-1492

1 reference

Accessories to the crime: functions of cells recruited to the tumor microenvironment

6 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

The tumour microenvironment as a target for chemoprevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Innate and adaptive immune cells in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Bone marrow-derived mesenchymal stem cells and the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Neutralizing tumor-promoting chronic inflammation: a magic bullet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Innate immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Decoding the patterns of self and nonself by the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Decisions about dendritic cells: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Matrix metalloproteinases: regulators of the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Microenvironmental regulation of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

The immune contexture in human tumours: impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Home sweet home: the tumor microenvironment as a haven for regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Paradoxical roles of the immune system during cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

T cell-dependent B cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

IDO is a nodal pathogenic driver of lung cancer and metastasis development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

CD20+ B cells: the other tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

The role of complement in tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

The future of immune checkpoint therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Targeting the tumor microenvironment to enhance antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Strategies for use of IL-10 or its antagonists in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

TGFbeta signalling: a complex web in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Trial Watch: Peptide-based anticancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

First oncolytic virus approved for melanoma immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Vascular normalization as an emerging strategy to enhance cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Bevacizumab plus ipilimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

T cell exclusion, immune privilege, and the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Immunogenic cell death in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Targeting cancer-derived adenosine: new therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

Vascular normalization in Rgs5-deficient tumours promotes immune destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW168

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDW168

1 reference

6 September 2017

1 reference